Listing Regulation

• Kancera publishes prospectus in connection with the company’s rights issue

  1 March 2024

• Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

  23 February 2024

• Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851

  17 November 2023

• Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

  19 May 2023

• Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma

  20 October 2022

• Kancera appoints Peter Selin as Executive Vice President Corporate Development

  6 December 2021

• Kancera provides an update on the development of the company’s pharmaceutical project and nominates a new drug candidate

  21 April 2021

• Interim Report for Kancera AB (publ) Q2 2016 January 1 – June 30, 2016

  19 August 2016

• Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016

  3 May 2016

• Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015

  19 February 2016